BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 29475932)

  • 1. Differences in Urinary Amino Acid Patterns in Individuals with Different Types of Urological Tumor Urinary Amino Acid Patterns as Markers of Urological Tumors.
    Duskova K; Vesely S; DO Carmo Silva J; Cernei N; Zitka O; Heger Z; Adam V; Havlova K; Babjuk M
    In Vivo; 2018; 32(2):425-429. PubMed ID: 29475932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urine microRNAs as potential noninvasive biomarkers in urologic cancers.
    Mlcochova H; Hezova R; Stanik M; Slaby O
    Urol Oncol; 2014 Jan; 32(1):41.e1-9. PubMed ID: 24035473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Molecular diagnostics in urologic oncology. Detection of nucleic acids in urine samples].
    Müller M; Goessl C; Krause H; Miller K
    Urologe A; 2003 May; 42(5):660-8. PubMed ID: 12750801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The clinical usefulness of urinary basic fetoprotein (BFP) in patients with urological malignancies].
    Tsujii T; Yonese J; Kojima S; Tari K; Ishii M; Seino Y
    Nihon Hinyokika Gakkai Zasshi; 1990 Jun; 81(6):829-34. PubMed ID: 1698231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Significance of current bio- and molecular-markers in urological cancers].
    Shimazui T; Akaza H
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):1008-14. PubMed ID: 15272577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of coagulation factors in urological malignancy: A prospective, controlled study on prostate, renal and bladder cancer.
    Alevizopoulos A; Tyritzis S; Leotsakos I; Anastasopoulou I; Pournaras C; Kotsis P; Katsarou O; Alamanis C; Stravodimos K; Constantinides C
    Int J Urol; 2017 Feb; 24(2):130-136. PubMed ID: 28004432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tumor markers in urological malignancies].
    Kuriyama M
    Nihon Rinsho; 1996 Jun; 54(6):1631-6. PubMed ID: 8691621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation study of urinary metabolites as potential biomarkers for prostate cancer detection.
    Gamagedara S; Kaczmarek AT; Jiang Y; Cheng X; Rupasinghe M; Ma Y
    Bioanalysis; 2012 Jun; 4(10):1175-83. PubMed ID: 22651561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomic studies in urological malignancies.
    Ferguson RE; Selby PJ; Banks RE
    Contrib Nephrol; 2004; 141():257-79. PubMed ID: 14650238
    [No Abstract]   [Full Text] [Related]  

  • 10. Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, gamma -synuclein, and catechol-o-methyltransferase) identified by proteomic analysis.
    Iwaki H; Kageyama S; Isono T; Wakabayashi Y; Okada Y; Yoshimura K; Terai A; Arai Y; Iwamura H; Kawakita M; Yoshiki T
    Cancer Sci; 2004 Dec; 95(12):955-61. PubMed ID: 15596044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Urine polyamine in patients with malignant urological diseases using a polyamine-test enzyme kit].
    Sakai S; Koide T; Ito Y; Tei K; Deguchi T; Matsuda S; Kato N; Ban Y; Nishiura T
    Hinyokika Kiyo; 1986 May; 32(5):661-5. PubMed ID: 3751793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor M2 pyruvate kinase in plasma of patients with urological tumors.
    Roigas J; Schulze G; Raytarowski S; Jung K; Schnorr D; Loening SA
    Tumour Biol; 2001; 22(5):282-5. PubMed ID: 11553857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary amino acid excretion: comparison of normal individuals and patients with bladder cancer.
    McGregor RF; Crawford R; Johnson DE; Brown B; Sharon MS; Johnston D
    Urology; 1977 May; 9(5):538-42. PubMed ID: 871045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies.
    Ellinger J; Müller DC; Müller SC; Hauser S; Heukamp LC; von Ruecker A; Bastian PJ; Walgenbach-Brunagel G
    Urol Oncol; 2012; 30(4):509-15. PubMed ID: 20870429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers.
    Wood SL; Knowles MA; Thompson D; Selby PJ; Banks RE
    Nat Rev Urol; 2013 Apr; 10(4):206-18. PubMed ID: 23443013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging Utility of Urinary Cell-free Nucleic Acid Biomarkers for Prostate, Bladder, and Renal Cancers.
    Lin SY; Linehan JA; Wilson TG; Hoon DSB
    Eur Urol Focus; 2017 Apr; 3(2-3):265-272. PubMed ID: 28753876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Urologic tumors in old age].
    Debruyne FM
    Tijdschr Gerontol Geriatr; 1986 Apr; 17(2):65-8. PubMed ID: 3715964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoimmune disease and subsequent urological cancer.
    Liu X; Ji J; Forsti A; Sundquist K; Sundquist J; Hemminki K
    J Urol; 2013 Jun; 189(6):2262-8. PubMed ID: 23228387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of amino acids in urine of patients with prostate cancer and benign prostate growth.
    Sroka WD; Boughton BA; Reddy P; Roessner U; Słupski P; Jarzemski P; Dąbrowska A; Markuszewski MJ; Marszałł MP
    Eur J Cancer Prev; 2017 Mar; 26(2):131-134. PubMed ID: 27222937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--NMP22 as a urinary marker for surveillance of bladder cancer. NMP22 Study Group].
    Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
    Gan To Kagaku Ryoho; 1997 May; 24(7):829-36. PubMed ID: 9170521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.